Search by Drug Name or NDC

    NDC 50419-0385-72 ALIQOPA 15 mg/mL Details

    ALIQOPA 15 mg/mL

    ALIQOPA is a INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Bayer HealthCare Pharmaceuticals Inc.. The primary component is COPANLISIB.

    Product Information

    NDC 50419-0385
    Product ID 50419-385_209c53a5-83dd-4eae-9f6f-66130657f8e7
    Associated GPIs 21538020102120
    GCN Sequence Number 077717
    GCN Sequence Number Description copanlisib di-HCl VIAL 60 MG INTRAVEN
    HIC3 V1Q
    HIC3 Description ANTINEOPLASTIC SYSTEMIC ENZYME INHIBITORS
    GCN 43837
    HICL Sequence Number 044503
    HICL Sequence Number Description COPANLISIB DI-HCL
    Brand/Generic Brand
    Proprietary Name ALIQOPA
    Proprietary Name Suffix n/a
    Non-Proprietary Name copanlisib
    Product Type HUMAN PRESCRIPTION DRUG
    Dosage Form INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
    Route INTRAVENOUS
    Active Ingredient Strength 15
    Active Ingredient Units mg/mL
    Substance Name COPANLISIB
    Labeler Name Bayer HealthCare Pharmaceuticals Inc.
    Pharmaceutical Class Kinase Inhibitor [EPC], Kinase Inhibitors [MoA]
    DEA Schedule n/a
    Marketing Category NDA
    Application Number NDA209936
    Listing Certified Through 2024-12-31

    Package

    NDC 50419-0385-72 (50419038572)

    NDC Package Code 50419-385-72
    Billing NDC 50419038572
    Package 1 VIAL, SINGLE-DOSE in 1 CARTON (50419-385-72) / 4 mL in 1 VIAL, SINGLE-DOSE
    Marketing Start Date 2018-10-30
    NDC Exclude Flag N
    Pricing Information N/A